Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | euchromatic histone-lysine N-methyltransferase 2 | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | hexokinase, putative | 0.0713 | 1 | 0.5 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.0283 | 0.0283 |
Toxoplasma gondii | hexokinase | 0.0713 | 1 | 1 |
Onchocerca volvulus | 0.0448 | 0.6075 | 0.6075 | |
Echinococcus multilocularis | hexokinase type 2 | 0.0713 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0487 | 0.6651 | 0.6651 |
Onchocerca volvulus | Hexokinase homolog | 0.0448 | 0.6075 | 0.6075 |
Brugia malayi | Hexokinase family protein | 0.0221 | 0.2727 | 0.2727 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0283 | 0.0283 |
Schistosoma mansoni | hexokinase | 0.0713 | 1 | 1 |
Brugia malayi | hexokinase type II | 0.0227 | 0.2816 | 0.2816 |
Trichomonas vaginalis | set domain proteins, putative | 0.0286 | 0.3691 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0227 | 0.2816 | 0.2816 |
Brugia malayi | Hexokinase family protein | 0.0713 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0283 | 0.0283 |
Onchocerca volvulus | 0.0713 | 1 | 1 | |
Echinococcus multilocularis | hexokinase | 0.0713 | 1 | 1 |
Onchocerca volvulus | 0.0713 | 1 | 1 | |
Plasmodium vivax | hexokinase, putative | 0.0713 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0283 | 0.0283 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.0283 | 0.0283 |
Trypanosoma cruzi | hexokinase, putative | 0.0713 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0713 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.0713 | 1 | 0.5 |
Onchocerca volvulus | 0.0286 | 0.3691 | 0.3691 | |
Trypanosoma brucei | hexokinase | 0.0713 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0448 | 0.6075 | 0.6075 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0283 | 0.0283 |
Loa Loa (eye worm) | hexokinase | 0.0713 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0283 | 0.0283 |
Loa Loa (eye worm) | hexokinase | 0.0221 | 0.2727 | 0.2727 |
Echinococcus granulosus | hexokinase | 0.0713 | 1 | 1 |
Plasmodium falciparum | hexokinase | 0.0713 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0713 | 1 | 1 |
Echinococcus multilocularis | hexokinase | 0.0713 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.0713 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0713 | 1 | 1 |
Onchocerca volvulus | 0.0713 | 1 | 1 | |
Brugia malayi | Hexokinase family protein | 0.0448 | 0.6075 | 0.6075 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0283 | 0.0283 |
Echinococcus granulosus | hexokinase type 2 | 0.0713 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0713 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.0713 | 1 | 1 |
Brugia malayi | Pre-SET motif family protein | 0.0251 | 0.3179 | 0.3179 |
Trypanosoma brucei | hexokinase, putative | 0.0713 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.0713 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 1 | 0.0713 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0227 | 0.2816 | 0.2816 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0251 | 0.3179 | 0.3179 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0283 | 0.0283 |
Leishmania major | hexokinase, putative | 0.0713 | 1 | 0.5 |
Treponema pallidum | hexokinase (hxk) | 0.0713 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | > 53 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS hits for small molecule agonists of the CRF-binding protein and CRF-R2 receptor complex. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | > 47.1 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS hits for small molecule antagonists of the CRF-binding protein and CRF-R2 receptor complex. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.7783 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540262] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488813] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.